ArticleDiscover oncology2025
Nomograms predicting cancer-specific survival and overall survival of advanced salivary gland malignancy patients: a study based on the SEER database.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo establish a clinical prediction model for specific and overall survival in advanced salivary gland malignant tumors, providing a potential reference tool for personalized clinical care and adjunct treatment decision-making.
methodsRetrospective data from the Surveillance, Epidemiology, and End Results (SEER) 8.4.3 version were utilized. Clinical variables collected included patient age, gender, race, diagnosis year, SERR historic stage A, histological types(The histological classification of advanced salivary gland malignant tumors in this study mainly include acinic cell carcinoma, adenoid cystic, mucoepidermoid carcinoma, salivary duct carcinoma, carcinoma ex pleomorphic adenoma, squamous cell carcinoma NOS, salivary gland carcinoma NOS and other histological types), T stage, N stage, M stage, treatment modalities (including surgery, radiotherapy, and chemotherapy), marital status, cancer-specific survival (CSS), overall survival (OS), and survival status. Patients diagnosed with TNM III/TNM IV stage salivary gland malignant tumors between 2010 and 2015 were allocated to the training set, while those diagnosed between 2004 and 2009 served as the test set. Chi-square test compared clinical variables between the training and test sets. Univariate and multivariate COX regression models identified prognostic factors, Kaplan-Meier analysis depicted survival curves, and predictive models for patient OS and CSS were constructed using R-studio environment, with calibration curves and C-index calculated. All statistical analyses were conducted using SPSS 25.0 and R-studio, with P < 0.05 considered significant.
resultsA total of 1477 late-stage salivary gland malignant tumor patients were included. Independent prognostic factors for OS included age, tumor histology, histologic types, T stage, M stage, surgery, and radiotherapy. CSS shared similar prognostic factors with OS. Predictive nomograms based on clinical variables showed high accuracy for 1, 2, 3, 5, and 10-year OS and CSS, with C-indexes of 0.748 and 0.783, respectively. External validation confirmed the models' accuracy, with well-fitted calibration curves between predicted and observed survival rates.
conclusionNomograms constructed from clinical data can effectively predict OS and CSS for advanced salivary gland malignant tumor patients, providing a potential reference tool for personalized clinical care and adjunct treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.